Compare VREX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | PRLD |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 391.1M |
| IPO Year | 2016 | 2020 |
| Metric | VREX | PRLD |
|---|---|---|
| Price | $10.55 | $4.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.67 | $5.67 |
| AVG Volume (30 Days) | 473.8K | ★ 560.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $811,000,000.00 | $12,140,000.00 |
| Revenue This Year | $5.35 | $320.10 |
| Revenue Next Year | $3.88 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $6.76 | $0.75 |
| 52 Week High | $14.57 | $5.69 |
| Indicator | VREX | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 43.30 |
| Support Level | $10.18 | $3.92 |
| Resistance Level | $10.87 | $5.52 |
| Average True Range (ATR) | 0.58 | 0.45 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 61.10 | 12.20 |
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.